This was tested as a monotherapy and in combination with pembrolizumab (anti PD-1) in patients with KRAS-mutated advanced or metastatic non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Here, KRAS is linked to familial pancreatic carcinoma.